Impact Biomedical (IBO) Liabilities and Shareholders Equity (2022 - 2026)

Impact Biomedical (IBO) has 5 years of Liabilities and Shareholders Equity data on file, last reported at $17.1 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 14.79% year-over-year to $17.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $71.8 million (down 45.29% YoY) and the FY2025 annual result came in at $17.4 million, down 14.22% from the prior year.
• Liabilities and Shareholders Equity fell to $17.1 million in Q1 2026, from $17.4 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $46.7 million in Q3 2024 to a low of $17.1 million in Q1 2026.
• A 5-year average of $33.0 million and a median of $44.1 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity climbed 3.58% — and 2025, when it slumped 61.01%.
• Tracing IBO's Liabilities and Shareholders Equity over 5 years: stood at $46.5 million in 2022, then declined by 4.01% to $44.6 million in 2023, then plunged by 54.54% to $20.3 million in 2024, then dropped by 14.22% to $17.4 million in 2025, then fell by 1.83% to $17.1 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $17.1 million (Q1 2026), $17.4 million (Q4 2025), and $18.2 million (Q3 2025), per Business Quant data.